All these experiences led to the development of the Revo-S file system, which was launched in 2009. This system enables a root-canal curettage with only three files. Revo-S is currently state-of-the-art technology; however, the development is ongoing, which is why we hold the AGE symposium every year.

In autumn 2009, MICRO-MEGA joined a group of companies to launch the Revo-S of SycoTec. In March of this year, the Canadian SciCan joined the European duo. The group is now amongst the top manufacturers of dental equipment worldwide. What opportunities does such a strong group offer?

One great asset is that we are able to join forces and learn from one another. Our focus here in Europe naturally lies in Germany and many are also going to enter new markets. If possible, we will use joint marketing, and joint research and development in order to consolidate our position on the market. An important part of the strategy is to maintain and further the SciCan and MICRO-MEGA brands.

Is the name of the group still under debate?

Indeed, we have debated this for a while but have finally agreed on a name. I am proud to announce that MICRO-MEGA, SciCan and SycoTec are members of the Sanavis Group.

MICRO-MEGA sells its products worldwide. Which countries are the most important in terms of turnover? And which regions hold the most potential in your opinion?

Europe has always played an important role in our corporate development. The most important markets are Germany and, in our domestic market, France. North and South America are in the process of development, particularly with the introduction of our rotary NITI systems. We have also recorded good growth figures in the Asia-Pacific region. Moreover, we are keenly observing the Middle Eastern region. As you can see, MICRO-MEGA as an internationally known brand is in the process of exploring current potential markets.

There is every chance of success, particularly in research and development in the group have now reached global player magnitudes and are now how to take advantage of this.

Dr Gruner, are you currently working on the development of new products?

Dr Stephan Gruner: Thanks to the abovementioned synergies, our newly created group is going to be able to do the dental world. We are constantly trying to maintain our technological lead and thus work hard and intensively. An event like the AGE helps keep MICRO-MEGAs finger on the pulse of world trends.

Have your expectations of this year’s AGE meeting been met?

The AGE meeting has once again helped us progress scientifically thanks to top-notch research results presented by the speakers. During our internal MICRO-MEGA sessions, we were able to discuss international market demands further, which were then tested for feasibility and formed into projects.

Prof Shimon Friedman lectured on The endodontic treatment outcome: The impact of the new technologies. Would you please summarise the most important points for us?

Prof Friedman is world-renowned in the field of endodontics. Together with co-authors Dr Thuan Dao et al., he authored the world famous Toronto Symposium 2006 special series of articles in the Journal of Endodontics. This is an extensive piece of work that illustrates and analyses the status of endodontics, starting with the publication of the first results in the year 2000 up to and including 2010.

In his excellent lecture, Prof Friedman made clear that differences in the evaluation and success or failure of an endodontic treatment depend on the methods and structure of the evaluating studies themselves. If the correct evaluation criteria are applied, the success rate of endodontic treatments over the last ten years is around 85% to 95%. Amongst the various authors, a high consistency of results is noticeable. These studies are encouraging.

The new product Revo-S was a part of further presentations. Dr Balto, in connection with the innovative Revo-S concept you also spoke about the ‘third dimension’ of endodontic treatment. Would you please illustrate the main points of the system?